Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside

Overview

Journal Drugs

Specialty Pharmacology

Date 2022 Jun 13

PMID 35696053

Authors

Chiara Palandri

Lorenzo Santini

Alessia Argiro

Francesca Margara

Ruben Doste

Alfonso Bueno-Orovio

Iacopo Olivotto

Raffaele Coppini

Affiliations

Soon will be listed here.

Abstract

Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the current guidelines are derived from small non-randomized studies, case series, or simply from the consensus of experts. Guideline-directed therapy of HCM includes non-selective drugs such as disopyramide, non-dihydropyridine calcium channel blockers, or β-adrenergic receptor blockers, mainly used in patients with symptomatic obstruction of the outflow tract. Following promising preclinical studies, several drugs acting on potential HCM-specific targets were tested in patients. Despite the huge efforts, none of these studies was able to change clinical practice for HCM patients, because tested drugs were proven to be scarcely effective or hardly tolerated in patients. However, novel compounds have been developed in recent years specifically for HCM, addressing myocardial hypercontractility and altered energetics in a direct manner, through allosteric inhibition of myosin. In this paper, we will critically review the use of different classes of drugs in HCM patients, starting from "old" established agents up to novel selective drugs that have been recently trialed in patients.

Citing Articles

Recent Clinical Updates of Hypertrophic Cardiomyopathy and Future Therapeutic Strategies.

Zhao M, He X, Min X, Yang H, Wu W, Zhong J Rev Cardiovasc Med. 2025; 26(2):25132.

PMID: 40026515 PMC: 11868910. DOI: 10.31083/RCM25132.

Hemodynamics in Left-Sided Cardiomyopathies.

Monaco G, Amata F, Battaglia V, Panico C, Condorelli G, Pinto G Rev Cardiovasc Med. 2025; 25(12):455.

PMID: 39742240 PMC: 11683717. DOI: 10.31083/j.rcm2512455.

Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies.

Zakynthinos G, Gialamas I, Tsolaki V, Pantelidis P, Goliopoulou A, Gounaridi M J Cardiovasc Dev Dis. 2024; 11(12).

PMID: 39728291 PMC: 11678468. DOI: 10.3390/jcdd11120401.

Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.

Verheyen N, Auer J, Bonaros N, Buchacher T, Dalos D, Grimm M Wien Klin Wochenschr. 2024; 136(Suppl 15):571-597.

PMID: 39352517 PMC: 11445290. DOI: 10.1007/s00508-024-02442-1.

An evidence review and gap analysis for obstructive hypertrophic cardiomyopathy.

Butzner M, Aronitz E, Cameron H, Tantakoun K, Shreay S, Drudge C BMC Cardiovasc Disord. 2024; 24(1):416.

PMID: 39127628 PMC: 11316357. DOI: 10.1186/s12872-024-04084-7.

References

Heitner S, Jacoby D, Lester S, Owens A, Wang A, Zhang D . Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. Ann Intern Med. 2019; 170(11):741-748. DOI: 10.7326/M18-3016. View

Walsh R, Horwitz L . Adverse hemodynamic effects of intravenous disopyramide compared with quinidine in conscious dogs. Circulation. 1979; 60(5):1053-8. DOI: 10.1161/01.cir.60.5.1053. View

Sacchetto C, Sequeira V, Bertero E, Dudek J, Maack C, Calore M . Metabolic Alterations in Inherited Cardiomyopathies. J Clin Med. 2019; 8(12). PMC: 6947282. DOI: 10.3390/jcm8122195. View

Santini L, Coppini R, Cerbai E . Ion Channel Impairment and Myofilament Ca Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy. Cells. 2021; 10(10). PMC: 8534456. DOI: 10.3390/cells10102789. View

Westermann D, Knollmann B, Steendijk P, Rutschow S, Riad A, Pauschinger M . Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail. 2005; 8(2):115-21. DOI: 10.1016/j.ejheart.2005.07.012. View

Ho C, Sweitzer N, McDonough B, Maron B, Casey S, Seidman J . Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002; 105(25):2992-7. DOI: 10.1161/01.cir.0000019070.70491.6d. View

Clippinger S, Cloonan P, Wang W, Greenberg L, Stump W, Angsutararux P . Mechanical dysfunction of the sarcomere induced by a pathogenic mutation in troponin T drives cellular adaptation. J Gen Physiol. 2021; 153(5). PMC: 8054178. DOI: 10.1085/jgp.202012787. View

Ho C, Lakdawala N, Cirino A, Lipshultz S, Sparks E, Abbasi S . Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2014; 3(2):180-8. PMC: 4323670. DOI: 10.1016/j.jchf.2014.08.003. View

Corral-Acero J, Margara F, Marciniak M, Rodero C, Loncaric F, Feng Y . The 'Digital Twin' to enable the vision of precision cardiology. Eur Heart J. 2020; 41(48):4556-4564. PMC: 7774470. DOI: 10.1093/eurheartj/ehaa159. View

10.

Chatterjee K, Raff G, Anderson D, Parmley W . Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents. Prog Cardiovasc Dis. 1982; 25(3):193-210. DOI: 10.1016/0033-0620(82)90016-0. View

11.

Spudich J . Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J. 2014; 106(6):1236-49. PMC: 3985504. DOI: 10.1016/j.bpj.2014.02.011. View

12.

Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S . Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004; 109(10):1284-91. PMC: 2779533. DOI: 10.1161/01.CIR.0000121426.43044.2B. View

13.

Schwartz P, Ackerman M, Antzelevitch C, Bezzina C, Borggrefe M, Cuneo B . Inherited cardiac arrhythmias. Nat Rev Dis Primers. 2020; 6(1):58. PMC: 7935690. DOI: 10.1038/s41572-020-0188-7. View

14.

Tyska M, Hayes E, Giewat M, Seidman C, Seidman J, Warshaw D . Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res. 2000; 86(7):737-44. DOI: 10.1161/01.res.86.7.737. View

15.

Frishman W . Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs. 2009; 7 Suppl 1:17-23. DOI: 10.2165/00129784-200707001-00003. View

16.

White P . Calcium channel blockers. AACN Clin Issues Crit Care Nurs. 1992; 3(2):437-46. DOI: 10.4037/15597768-1992-2015. View

17.

Wilder T, Ryba D, Wieczorek D, Wolska B, Solaro R . N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2015; 309(10):H1720-30. PMC: 4666985. DOI: 10.1152/ajpheart.00339.2015. View

18.

Anderson R, Trivedi D, Sarkar S, Henze M, Ma W, Gong H . Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018; 115(35):E8143-E8152. PMC: 6126717. DOI: 10.1073/pnas.1809540115. View

19.

Wilson W, Criley J, Ross R . Dynamics of left ventricular emptying in hypertrophic subaortic stenosis. A cineangiographic and hemodynamic study. Am Heart J. 1967; 73(1):4-16. DOI: 10.1016/0002-8703(67)90303-1. View

20.

Cohen L, Braunwald E . Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967; 35(5):847-51. DOI: 10.1161/01.cir.35.5.847. View